Evidence of such a mechanism for TILs in ovarian carcinoma is still sparse (Raspollini et al, 2005; Yang et al, 2007), especially as the rate of HER2/neu-expressing tumour cells varies from 1.9 to 35% (Press et al, 2005). The gene discussed is ERBB2; the disease is neoplasm.